Rna-nanostructured double robots and methods of use thereof

A method of inhibiting tumor growth in a human subject, comprising administering to the subject a therapeutically effective amount of the composition comprising:

• an RNA nanostructure robot having the sequence of (R3)n—NR1-L-NR2—(R4)m, wherein:
• NR1 and NR2 independently represent an RNA nanostructure each comprising a nucleic acid sequence having at least about 90% sequence identity to SEQ ID NO:1 or SEQ ID NO:
• 9 that self-assembles into respective first and second scaffolds;
• L is a linker which operably links NR1 to NR2;
• wherein R3 and R4 are independently selected from a pair of fastener strands, an aptamer, a cargo molecule, a capture strand, a targeting strand, and H;
• n is an integer from 1 to 20;
• and
• m is an integer from 0 to 20,
• and a pharmaceutically acceptable carrier.

A method of inducing a tumor necrosis response in a human subject, comprising administering to the subject a therapeutically effective amount of the composition comprising:

• an RNA nanostructure robot having the sequence of (R3)n—NR1-L-NR2—(R4)m, wherein:
• NR1 and NR2 independently represent an RNA nanostructure each comprising a nucleic acid sequence having at least about 90% sequence identity to SEQ ID NO:1 or SEQ ID NO:
• 9 that self-assembles into respective first and second scaffolds;
• L is a linker which operably links NR1 to NR2;
• Preliminary Amendment dated Jan. 24, 2022 wherein R3 and R4 are independently selected from a pair of fastener strands, an aptamer, a cargo molecule, a capture strand, a targeting strand, and H;
• n is an integer from 1 to 20;
• and
• m is an integer from 0 to 20,
• and a pharmaceutically acceptable carrier.

A method for the prophylactic or therapeutic treatment of cancer in a human subject, comprising administering to the subject a therapeutically effective amount of the composition comprising:

• an RNA nanostructure robot having the sequence of (R3)n—NR1-L-NR2—(R4)m, wherein:
• NR1 and NR2 independently represent an RNA nanostructure each comprising a nucleic acid sequence having at least about 90% sequence identity to SEQ ID NO:1 or SEQ ID NO:
• 9 that self-assembles into respective first and second scaffolds;
• L is a linker which operably links NR1 to NR2;
• wherein R3 and R4 are independently selected from a pair of fastener strands, an aptamer, a cargo molecule, a capture strand, a targeting strand, and H;
• n is an integer from 1 to 20;
• and
• m is an integer from 0 to 20,
• and a pharmaceutically acceptable carrier.

A method of activating or stimulating the immune system by triggering the toll-like receptor 3 (TLR3) signaling pathway in a human subject, the method comprising administering to the subject a therapeutically effective amount of the composition comprising:

• an RNA nanostructure robot having the sequence of (R3)n—NR1-L-NR2—(R4)m, wherein:
• NR1 and NR2 independently represent an RNA nanostructure each comprising a nucleic acid sequence having at least about 90% sequence identity to SEQ ID NO:1 or SEQ ID NO:
• 9 that self-assembles into respective first and second scaffolds;
• L is a linker which operably links NR1 to NR2;
• wherein R3 and R4 are independently selected from a pair of fastener strands, an aptamer, a cargo molecule, a capture strand, a targeting strand, and H;
• n is an integer from 1 to 20;
• and
• m is an integer from 0 to 20,
• and a pharmaceutically acceptable carrier.